Open Access

Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study

  • Authors:
    • Juncheng Li
    • Peng Sun
    • Tao Huang
    • Shengdong He
    • Lingfan Li
    • Gang Xue
  • View Affiliations

  • Published online on: November 9, 2020     https://doi.org/10.3892/ol.2020.12282
  • Article Number: 21
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

ERCC1, RRM1, TUBB3, TYMS and TOP2A genes have been shown to be associated with drug resistance in various types of tumors; however, their roles in breast cancer chemotherapy have not been fully validated. In the present study, 140 well‑matched patients with breast cancer, comprising 70 patients receiving individualized chemotherapy and 70 receiving classic chemotherapy, were analyzed. In the individualized chemotherapy group, the mRNA expression levels of ERCC1, RRM1, TUBB3, TYMS and TOP2A in breast cancer tissues were measured using multiplex branched DNA liquidchip technology prior to chemotherapy; an individualized chemotherapy regimen was developed for each patient according to the results. As a control, patients in the classic chemotherapy group received a docetaxel + epirubicin + cyclophosphamide regimen. Survival analyses were performed using the Kaplan‑Meier method. The prognostic factors for disease‑free survival (DFS) and overall survival (OS) in the patients were identified via Cox's proportional hazards regression model. Adverse reactions were evaluated according to the National Cancer Institute Common Toxicity Criteria 4. Compared with the classic chemotherapy group, the DFS and OS of the individualized chemotherapy group were significantly longer (DFS, 77.4 vs. 67.1 months, P=0.039; OS, 81.4 vs. 75.4 months, P=0.031), and the incidence of grade 2 or 3 palpitations and chest tightness was lower (12.9 vs. 27.1%, P=0.035). The chemotherapy strategy guided by genetic detection was an independent protection factor for DFS [hazard ratio (HR)=0.389, 95% confidence interval (CI): 0.153, 0.989, P=0.047], but not an independent protection factor for OS (HR=0.340, 95% CI: 0.107, 1.078, P=0.067). The results indicate that the combined detection of ERCC1, RRM1, TUBB3, TYMS and TOP2A gene expression and use of the results to guide individualized chemotherapy can improve treatment efficacy and reduce unnecessary toxicity.
View Figures
View References

Related Articles

Journal Cover

January-2021
Volume 21 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li J, Sun P, Huang T, He S, Li L and Xue G: Individualized chemotherapy guided by the expression of <em>ERCC1, RRM1, TUBB3, TYMS</em> and <em>TOP2A</em> genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study. Oncol Lett 21: 21, 2021
APA
Li, J., Sun, P., Huang, T., He, S., Li, L., & Xue, G. (2021). Individualized chemotherapy guided by the expression of <em>ERCC1, RRM1, TUBB3, TYMS</em> and <em>TOP2A</em> genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study. Oncology Letters, 21, 21. https://doi.org/10.3892/ol.2020.12282
MLA
Li, J., Sun, P., Huang, T., He, S., Li, L., Xue, G."Individualized chemotherapy guided by the expression of <em>ERCC1, RRM1, TUBB3, TYMS</em> and <em>TOP2A</em> genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study". Oncology Letters 21.1 (2021): 21.
Chicago
Li, J., Sun, P., Huang, T., He, S., Li, L., Xue, G."Individualized chemotherapy guided by the expression of <em>ERCC1, RRM1, TUBB3, TYMS</em> and <em>TOP2A</em> genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study". Oncology Letters 21, no. 1 (2021): 21. https://doi.org/10.3892/ol.2020.12282